Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Anu Lipsanen"'
Autor:
Asla Pitkänen, Noora Huusko, Xavier Ekolle Ndode-Ekane, Jenni Kyyriäinen, Anssi Lipponen, Anu Lipsanen, Alejandra Sierra, Tamuna Bolkvadze
Publikováno v:
Neurobiology of Disease, Vol 72, Iss , Pp 224-232 (2014)
Disease modification of epilepsy refers to the alleviation of epileptogenesis or comorbidities after genetic or acquired epileptogenic brain insults. There are currently 30 proof-of-concept experimental pharmacologic studies that have demonstrated so
Externí odkaz:
https://doaj.org/article/8f4ecbfa7d1043cf95c4ee94b3bed39a
Autor:
Anu Lipsanen, Stefanie Flunkert, Kristina Kuptsova, Mikko Hiltunen, Manfred Windisch, Birgit Hutter-Paier, Jukka Jolkkonen
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e60235 (2013)
Experimental studies have identified a complex link between neurodegeneration, β-amyloid (Aβ) and calcium homeostasis. Here we asked whether early phase β-amyloid pathology in transgenic hAPPSL mice exaggerates the ischemic lesion and remote secon
Externí odkaz:
https://doaj.org/article/3c7f8d5e5db348428d4516f2b2885dac
Autor:
Anu Lipsanen, Wolfgang Löscher, Olli Gröhn, Albert J. Becker, Teresa Ravizza, Michele Simonato, Niina Lapinlampi, Jan A. Gorter, Merab Kokaia, Jussi Paananen, Asla Pitkänen, Cristophe Bernard, Eleonora Aronica, Jens P. Bankstahl, Esbjörn Melin, Annamaria Vezzani, Paolo Roncon, Katarzyna Lukasiuk
Publikováno v:
Epilepsy Research, 129, 87-90. Elsevier
Epilepsy Research
Epilepsy Research, Elsevier, 2017, 129, pp.87-90. ⟨10.1016/j.eplepsyres.2016.11.010⟩
Epilepsy research, 129, 87-90. Elsevier
Epilepsy Research
Epilepsy Research, Elsevier, 2017, 129, pp.87-90. ⟨10.1016/j.eplepsyres.2016.11.010⟩
Epilepsy research, 129, 87-90. Elsevier
Article
Lack of translation of data obtained in preclinical trials to clinic has kindled researchers to develop new methodologies to increase the power and reproducibility of preclinical studies. One approach relates to harmonization of data col
Lack of translation of data obtained in preclinical trials to clinic has kindled researchers to develop new methodologies to increase the power and reproducibility of preclinical studies. One approach relates to harmonization of data col
Autor:
Anu Lipsanen, Saara Parkkinen, Mikko Hiltunen, Jukka Jolkkonen, Petra Mäkinen, Sirpa Peräniemi, Joonas Khabbal
Publikováno v:
Neuroscience Letters. 580:173-177
Remote areas connected to cortical infarcts, such as the thalamus, are affected by stroke due to delayed retrograde degeneration of afferent connections. This is temporally associated with the accumulation of β-amyloid (Aβ) and calcium. Here we tes
Autor:
Anu Lipsanen, Timo Sarajärvi, Jukka Jolkkonen, Mikko Hiltunen, Sirpa Peräniemi, Hilkka Soininen, Petra Mäkinen, Annakaisa Haapasalo
Publikováno v:
Journal of Cellular and Molecular Medicine
Alzheimer's disease (AD) and cerebral ischaemia share similar features in terms of altered amyloid precursor protein (APP) processing and β-amyloid (Aβ) accumulation. We have previously shown that Aβ and calcium deposition, and β-secretase activi
Autor:
Jukka Jolkkonen, Anu Lipsanen
Publikováno v:
Cellular and Molecular Life Sciences. 68:3007-3017
Valid experimental models and behavioral tests are indispensable for the development of therapies for stroke. The translational failure with neuroprotective drugs has forced us to look for alternative approaches. Restorative therapies aiming to facil
Autor:
Anne Marjamäki, Beate Eckes, Marika Ojala, Jonna Nieminen, Olli T. Pentikäinen, Heli Lappalainen, Annukka Jouppila, Jyrki Heino, Liisa Nissinen, Riitta Lassila, Mark S. Johnson, Anu Lipsanen, Jarmo Käpylä
Publikováno v:
Thrombosis and Haemostasis. 103:387-397
SummaryInteraction of blood platelets with vascular collagen is an initiating event in haemostasis and thrombus formation. Based on molecular modelling of human integrin α2I domain and cell-based screening assays we have developed sulfonamide deriva
Autor:
Jenni Kyyriäinen, Anssi Lipponen, Anu Lipsanen, Xavier Ekolle Ndode-Ekane, Tamuna Bolkvadze, Alejandra Sierra, Noora Huusko, Asla Pitkänen
Publikováno v:
Neurobiology of Disease, Vol 72, Iss, Pp 224-232 (2014)
Disease modification of epilepsy refers to the alleviation of epileptogenesis or comorbidities after genetic or acquired epileptogenic brain insults. There are currently 30 proof-of-concept experimental pharmacologic studies that have demonstrated so
Autor:
Omar Touzani, Giedrius Kalesnykas, Mikko Hiltunen, Jukka Jolkkonen, Myriam Bernaudin, Anu Lipsanen, Ritva Vanninen, Palma Pro-Sistiaga
Publikováno v:
Experimental Neurology
Experimental Neurology, 2013, 248, pp.224-227. ⟨10.1016/j.expneurol.2013.06.016⟩
Experimental Neurology, Elsevier, 2013, 248, pp.224-227. ⟨10.1016/j.expneurol.2013.06.016⟩
Experimental Neurology, 2013, 248, pp.224-227. ⟨10.1016/j.expneurol.2013.06.016⟩
Experimental Neurology, Elsevier, 2013, 248, pp.224-227. ⟨10.1016/j.expneurol.2013.06.016⟩
Remote regions such as the thalamus undergo secondary degeneration after cerebral ischemia. In rodents, the pathology in the thalamus is characterized by a robust inflammatory reaction, β-amyloid (Aβ) accumulation and calcification. Here we studied
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974746eecd5c9374e25ab9fd80085149
https://hal.science/hal-01768814
https://hal.science/hal-01768814
Publikováno v:
Pharmacology, biochemistry, and behavior. 99(3)
Anti-inflammatory drug ibuprofen decreases the β-amyloid (Aβ) deposition and associated inflammation in transgenic Alzheimer disease mice. Based on this, we studied whether ibuprofen could modulate the secondary pathology described in the thalamus